Delving into the Latest Updates on Jecho Biopharmaceuticals Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Jecho Biopharmaceuticals Co., Ltd., located in the Sino-Singapore Tianjin Eco-city, is a Sino-foreign joint venture and high-tech enterprise focused on the R&D, production, and sales of biopharmaceuticals. Offering innovative and competitive biologics including monoclonal antibodies, recombinant proteins, oncolytic viruses, immunotoxins, and vaccines, it serves a global clientele with value-added products and services.

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

Fusion protein

Bispecific antibody

Bispecific T-cell Engager (BiTE)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	12
Immune System Diseases	3
Infectious Diseases	3
Hemic and Lymphatic Diseases	3
Nervous System Diseases	1

Top 5 Drug Type	Count

Fusion protein	5
Bispecific antibody	3
Bispecific T-cell Engager (BiTE)	2
Antibody drug conjugate (ADC)	1
Monoclonal antibody	1

Top 5 Target	Count

MSLN(Mesothelin)	1
VEGF-A(Vascular endothelial growth factor A)	1
CD3 x PRLR	1
CD3 x EpCAM	1
HER2 x HER3	1

Ia期主要目的：评价JL18008注射液在健康成年受试者中单次肌肉注射的安全性、耐受性。次要目的：评价JL18008注射液在健康成年受试者中单次肌肉注射的药代动力学（PK）特征；初步评价JL18008注射液在健康成年受试者中单次肌肉注射的药效动力学（PD）特征；初步评价JL18008注射液在健康成年受试者中单次肌肉注射的免疫原性。

[Translation]

Phase Ia Main purpose: To evaluate the safety and tolerability of a single intramuscular injection of JL18008 injection in healthy adult subjects. Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of a single intramuscular injection of JL18008 injection in healthy adult subjects; To preliminarily evaluate the pharmacodynamic (PD) characteristics of a single intramuscular injection of JL18008 injection in healthy adult subjects; To preliminarily evaluate the immunogenicity of a single intramuscular injection of JL18008 injection in healthy adult subjects.

Start Date13 Jun 2024

Sponsor / Collaborator

Jieku (Shanghai) Biomedical Research Co., Ltd.

CTR20223129 / Active, not recruitingPhase 1

JL14001注射液在健康成年受试者中单次给药、剂量递增的药代动力学、药效学、安全性、耐受性的I期临床研究

[Translation] A phase I clinical study of the pharmacokinetics, pharmacodynamics, safety and tolerability of JL14001 injection in healthy adult subjects with a single dose and increasing dose

主要目的：评价JL14001注射液在健康成年受试者中的安全性、耐受性。次要目的：评价JL14001注射液在健康成年受试者中的药代动力学（PK）特征；初步评价JL14001注射液在健康成年受试者中的药效动力学（PD）特征；初步评价JL14001注射液在健康成年受试者中的免疫原性；初步评估短效EPO产品-益比奥及长效EPO产品-耐斯宝分别与JL14001注射液的剂量换算关系和PD特征。

[Translation]

Primary purpose: Evaluate the safety and tolerability of JL14001 injection in healthy adult subjects. Secondary purpose: Evaluate the pharmacokinetic (PK) characteristics of JL14001 injection in healthy adult subjects; Preliminary evaluation of the pharmacodynamic (PD) characteristics of JL14001 injection in healthy adult subjects; Preliminary evaluation of the immunogenicity of JL14001 injection in healthy adult subjects; Preliminary evaluation of the dose conversion relationship and PD characteristics of the short-acting EPO product - EPIAO and the long-acting EPO product - Nicebo with JL14001 injection respectively.

Start Date07 Apr 2023

Sponsor / Collaborator

Jieku (Shanghai) Biomedical Research Co., Ltd.

CTR20221827 / RecruitingPhase 1

JL15003注射液治疗复发胶质母细胞瘤患者的安全性和耐受性临床研究

[Translation] Clinical study on the safety and tolerability of JL15003 injection in the treatment of patients with recurrent glioblastoma

主要目的：评价JL15003注射液治疗复发胶质母细胞瘤患者的安全性和耐受性。次要目的：初步评价JL15003对复发胶质母细胞瘤患者的疗效，为II期临床试验的给药剂量提供依据；观察JL15003在瘤内给药后的病毒脱落情况；探索复发胶质母细胞瘤患者肿瘤组织中与JL15003疗效相关的生物标志物。

[Translation]

Main purpose: Evaluate the safety and tolerability of JL15003 injection in the treatment of patients with recurrent glioblastoma. Secondary purpose: Preliminary evaluation of the efficacy of JL15003 in patients with recurrent glioblastoma, and provide a basis for the dosing of Phase II clinical trials; Observe the viral shedding of JL15003 after intratumoral administration; Explore biomarkers related to the efficacy of JL15003 in tumor tissues of patients with recurrent glioblastoma.

Start Date14 Oct 2022

Sponsor / Collaborator

Jecho Biopharmaceuticals Co., Ltd.

100 Clinical Results associated with Jecho Biopharmaceuticals Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Jecho Biopharmaceuticals Co., Ltd.

Login to view more data

23

Literatures (Medical) associated with Jecho Biopharmaceuticals Co., Ltd.

01 Dec 2024·Carbohydrate Polymers

Self-enhanced PTX@HSA-HA loaded functionalized injectable hydrogel for effective local chemo-photothermal therapy in breast cancer

Article

Author: Zhang, Wen ; Gao, Hang ; Wang, Yudie ; Li, Hang ; Shao, Shuaiqiang ; Meng, Xin ; Liu, Guangchun ; Tan, Lintongqing ; Li, Dawei ; Zhu, Tao

Breast cancer is a malignant tumor that poses a significant threat to women's health and single therapy fails to play a good oncological therapeutic effect. Synergistic treatment with multiple strategies may make up for the deficiencies and has gained widespread attention. In this study, sulfhydryl-modified hyaluronic acid (HA-SH) was covalently crosslinked with polydopamine (PDA) via a Michael addition reaction to develop an injectable hydrogel, in which PDA can be used not only as a matrix but also as a photothermal agent. After HSA and paclitaxel were spontaneously organized into nanoparticles via hydrophobic interaction, hyaluronic acid with low molecular weight was covalently linked to HSA, thus conferring effectively delivery. This photothermal injectable hydrogel incorporates PTX@HSA-HA nanoparticles, thereby initiating a thermochemotherapeutic response to target malignancy. Our results demonstrated that this injectable hydrogel possesses consistent drug delivery capability in a murine breast cancer model, collaborating with photothermal therapy to effectively suppress tumor growth, represented by low expression of Ki-67 and increasing apoptosis. Photothermal therapy (PTT) can effectively stimulate immune response by increasing IL-6 and TNF-α. Notably, the treatment did not elicit any indications of toxicity. This injectable hydrogel holds significant promise as a multifaceted therapeutic agent that integrates photothermal and chemotherapeutic modalities.

01 May 2024·Carbohydrate Polymers

Oxidized cellulose-filled double thermo/pH-sensitive hydrogel for local chemo-photothermal therapy in breast cancer

Article

Author: Meng, Xin ; Cui, Haoran ; Zhang, Zijian ; Liu, Guangchun ; Lin, Song ; Wang, Xin ; Liu, Jie

Lumpectomy plus radiation is a treatment option offering better survival than conventional mastectomy for patients with early-stage breast cancer. However, successive radioactive therapy remains tedious and unsafe with severe adverse reactions and secondary injury. Herein, a composite hydrogel with pH- and photothermal double-sensitive activity is developed via physical crosslinking. The composite hydrogel incorporated with tempo-oxidized cellulose nanofiber (TOCN), polyvinyl alcohol (PVA) and a polydopamine (PDA) coating for photothermal therapy (PTT) triggered in situ release of doxorubicin (DOX) drug was utilized to optimize postoperative strategies of malignant tumors inhibition. The incorporation of TOCN significantly affects the performance of composite hydrogels. The best-performing TOCN/PVA7 was selected for drug loading and polydopamine coating by rational design. In vitro studies have demonstrated that the composite hydrogel exhibited high NIR photothermal conversion efficiency, benign cytotoxicity to L929 cells, pH-dependent release profiles, and strong MCF-7 cell inhibitory effects. Then the TOCN/PVA7-PDA@DOX hydrogel is implanted into the tumor resection cavity for local in vivo chemo-photothermal synergistical therapy to ablate residue tumor tissues. Overall, this work suggests that such a chemo-photothermal hydrogel delivery system has great potential as a promising tool for the postsurgical management of breast cancer.

01 Jul 2023·Heliyon

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies

Article

Author: Xie, Yueqing ; Zhu, Jianwei ; Han, Lei ; Liu, Junjun ; Pan, Zhidi ; Xiao, Xiaodong ; Yuan, Yunsheng ; Jiang, Hua ; Bian, Yanlin ; Yue, Yali ; Wu, Mingyuan ; Chen, Jie ; Zhang, Baohong

CD22, as the B-cell malignancies antigen, has been targeted for immunotherapies through CAR-T cells, antibody-drug conjugates (ADCs) and immunotoxins via interaction of antibodies with binding domains on the receptor. We hypothesized that avidity and binding domain of antibody to target cells may have significant impact on the biological function in tumor immunotherapy, and T cell-engaging bispecific antibody (TCB) targeting CD22 could be used in the therapy of hematologic malignancies. So, to address the question, we utilized the information of six previously reported CD22 mAbs to generate CD22-TCBs with different avidity to different domains on CD22 protein. We found that the avidity of CD22-TCBs to protein was not consistent with the avidity to target cells, indicating that TCBs had different binding mode to the protein and cells. In vitro results indicated that CD22-TCBs mediated cytotoxicity depended on the avidity of antibodies to target cells rather than to protein. Moreover, distal binding domain of the antigen contributed to the avidity and biological activity of IgG-[L]-scfv-like CD22-TCBs. The T cells' proliferation, activation, cytotoxicity as well as cytokine release were compared, and G5/44 BsAb was selected for further in vivo assessment in anti-tumor activity. In vivo results demonstrated that CD22-TCB (G5/44 BsAb) significantly inhibited the tumors growth in mice. All these data suggested that CD22-TCBs could be developed as a promising candidate for B-cell malignancies therapy through optimizing the design with avidity and binding domain to CD22 target in consideration.

100 Deals associated with Jecho Biopharmaceuticals Co., Ltd.

Login to view more data

100 Translational Medicine associated with Jecho Biopharmaceuticals Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

8

Preclinical

IND Application

1

5

Phase 1 Clinical

Phase 3 Clinical

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Ranibizumab biosimilar (Jecho Biopharmaceuticals) ( VEGF-A )	Wet age-related macular degeneration More	Phase 3
CDMO-001	Neoplasms More	Phase 1
JL-18008	HIV Infections More	Phase 1
JL14001 ( EPO receptor )	chronic renal failure anemia More	Phase 1
COVID-19 No.1	COVID-19 More	Phase 1